Noxopharm (ASX:NOX) reports 200-fold TLR8 amplification in human biopsies, backed by a US patent and Nature Immunology paper.
Small Caps Stocks
NeuroScientific (ASX:NSB) reported an 80% response rate in fistulising Crohn’s and is launching a second Phase 2 trial to fast-track Australian approval.
Strickland Metals (ASX:STK) lifts Gradina resource 50% to 1.8Moz, taking Rogozna to 9.24Moz AuEq as PFS workstreams begin.
Osteopore (ASX:OSX) secures Hainan FDA approval at Shanghai Ruijin Hospital, opening an accelerated pathway into China’s US$2.5 billion orthopaedic devices market.
Adveritas (ASX:AV1) lifted ARR to A$16.3 million and its SME self-serve platform is converting organically before paid marketing even begins.
Strata management software provider Urbanise (ASX:UBN) is winning the battle of customer conversion!
Urbanise.com (ASX:UBN) booked A$700k of legacy strata conversions, confirmed Darc Rasmussen as Executive Chairman, and ships its AI Assistant in June 2026.
Kogan.com (ASX:KGN) lifted Adjusted EBIT 43% at its core business and Mighty Ape’s margin finally turned, reshaping the FY26 earnings story.
Viva Leisure (ASX:VVA) lifted its profit, but its not being derived from where investors think it is
Viva Leisure (ASX:VVA) upgrades FY26 NPAT guidance above $12m as TPLR grows 30% and corporate clubs hit record 80% utilisation.
Hawsons Iron (ASX:HIO) lifts its PFS NPV 37% to A$1.87 billion after a TAKRAF conveyor optimisation, but a A$4.34 billion funding gap remains.
Aroa Biosurgery (ASX:ARX) printed NZ$12.6m EBITDA in FY26 then guided FY27 lower as it reinvests NZ$9m into Myriad and Symphony.
